162 related articles for article (PubMed ID: 25823816)
21. Identification of BMP2 as an epigenetically silenced growth inhibitor in rhabdomyosarcoma.
Wolf S; Hagl B; Kappler R
Int J Oncol; 2014 May; 44(5):1727-35. PubMed ID: 24585058
[TBL] [Abstract][Full Text] [Related]
22. Profiling the molecular difference between Patched- and p53-dependent rhabdomyosarcoma.
Kappler R; Bauer R; Calzada-Wack J; Rosemann M; Hemmerlein B; Hahn H
Oncogene; 2004 Nov; 23(54):8785-95. PubMed ID: 15480423
[TBL] [Abstract][Full Text] [Related]
23. Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer.
Wolf I; Bose S; Desmond JC; Lin BT; Williamson EA; Karlan BY; Koeffler HP
Breast Cancer Res Treat; 2007 Oct; 105(2):139-55. PubMed ID: 17295047
[TBL] [Abstract][Full Text] [Related]
24. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma.
Hahn H; Wojnowski L; Specht K; Kappler R; Calzada-Wack J; Potter D; Zimmer A; Müller U; Samson E; Quintanilla-Martinez L; Zimmer A
J Biol Chem; 2000 Sep; 275(37):28341-4. PubMed ID: 10884376
[TBL] [Abstract][Full Text] [Related]
25. miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma.
Diao Y; Guo X; Jiang L; Wang G; Zhang C; Wan J; Jin Y; Wu Z
J Biol Chem; 2014 Jan; 289(1):529-39. PubMed ID: 24247238
[TBL] [Abstract][Full Text] [Related]
26. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
27. Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers.
Yuan BZ; Durkin ME; Popescu NC
Cancer Genet Cytogenet; 2003 Jan; 140(2):113-7. PubMed ID: 12645648
[TBL] [Abstract][Full Text] [Related]
28. DNA methylation and MeCP2 regulation of PTCH1 expression during rats hepatic fibrosis.
Yang JJ; Tao H; Huang C; Shi KH; Ma TT; Bian EB; Zhang L; Liu LP; Hu W; Lv XW; Li J
Cell Signal; 2013 May; 25(5):1202-11. PubMed ID: 23333245
[TBL] [Abstract][Full Text] [Related]
29. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
30. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells.
Kim TY; Jong HS; Song SH; Dimtchev A; Jeong SJ; Lee JW; Kim TY; Kim NK; Jung M; Bang YJ
Oncogene; 2003 Jun; 22(25):3943-51. PubMed ID: 12813468
[TBL] [Abstract][Full Text] [Related]
31. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines.
Sekita N; Suzuki H; Ichikawa T; Kito H; Akakura K; Igarashi T; Nakayama T; Watanabe M; Shiraishi T; Toyota M; Yoshie O; Ito H
Jpn J Cancer Res; 2001 Sep; 92(9):947-51. PubMed ID: 11572762
[TBL] [Abstract][Full Text] [Related]
33. Characteristic overexpression of the forkhead box transcription factor Foxf1 in Patched-associated tumors.
Wendling DS; Lück C; von Schweinitz D; Kappler R
Int J Mol Med; 2008 Dec; 22(6):787-92. PubMed ID: 19020777
[TBL] [Abstract][Full Text] [Related]
34. Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.
McKelvey BA; Gilpatrick T; Wang Y; Timp W; Umbricht CB; Zeiger MA
Thyroid; 2020 Oct; 30(10):1470-1481. PubMed ID: 32228178
[No Abstract] [Full Text] [Related]
35. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.
Zhang C; Li H; Zhou G; Zhang Q; Zhang T; Li J; Zhang J; Hou J; Liew CT; Yin D
J Pathol; 2007 Jun; 212(2):134-42. PubMed ID: 17471463
[TBL] [Abstract][Full Text] [Related]
36. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
[TBL] [Abstract][Full Text] [Related]
37. Hedgehog pathway activity in the LADY prostate tumor model.
Gipp J; Gu G; Crylen C; Kasper S; Bushman W
Mol Cancer; 2007 Mar; 6():19. PubMed ID: 17343742
[TBL] [Abstract][Full Text] [Related]
38. Hedgehog signalling in medulloblastoma, glioblastoma and neuroblastoma.
Shahi MH; Lorente A; Castresana JS
Oncol Rep; 2008 Mar; 19(3):681-8. PubMed ID: 18288402
[TBL] [Abstract][Full Text] [Related]
39. Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.
Meng CF; Zhu XJ; Peng G; Dai DQ
Oncol Rep; 2009 Nov; 22(5):1221-7. PubMed ID: 19787243
[TBL] [Abstract][Full Text] [Related]
40. Aberrant promoter methylation of the ABCG2 gene in renal carcinoma.
To KK; Zhan Z; Bates SE
Mol Cell Biol; 2006 Nov; 26(22):8572-85. PubMed ID: 16954373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
